Mycapssa

Mycapssa is a medicine used for the maintenance (long-term) treatment of acromegaly (a condition where the body produces too much growth hormone, leading to excessive growth of body tissue and bones, particularly of the hands, feet and face). Mycapssa can be used in adults who have previously responded to and tolerated treatment with other somatostatin analogues (synthetic versions of the hormone somatostatin). Mycapssa is a ‘hybrid medicine’, meaning that it is similar to a ‘reference medicine’ containing the same active substance, but there are certain differences between the two. The reference medicine for Mycapssa is Sandostatin IR, which is a solution given as an injection or infusion (drip), whereas Mycapssa is a capsule given by mouth. Acromegaly is rare, and Mycapssa was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 5 August 2013. Mycapssa contains the active substance octreotide.